Geographic region influences pharmacy's dispensing of blood glucose test strips
TO THE EDITOR: International pharmacy practice guidelines recognize the importance of self-monitoring of blood glucose (SMBG) for patients with diabetes and promote the role of community pharmacy in supporting patients performing SMBG. 1,2 However, large differences in the rate of dispensing of test strips exist among pharmacies in the Netherlands. 3 We assessed whether variations in dispensing of blood glucose test strips can be explained by patient characteristics and geographic region.
Methods. We used data from the PHARMO -record linkage system, containing all dispensing records of 950 000 residents of 25 population-defined areas in the Netherlands. 4 The study population consisted of all incident patients with type 1 and 2 diabetes from 1991 to 2001. Complete dispensing data during that period were extracted. Using a Cox proportional hazard model, we studied the association between the community pharmacy in which the patient was registered and the time to the first test strips dispensed.
Results.
Of 8233 incident patients, 19.4% were dispensed test strips at least once. Patient characteristics varied between pharmacies and, to a lesser extent, between regions. After having adjusted for these differences, the patient's community pharmacy was still independently associated with the use of test strips. Furthermore, the variation in dispensing of test strips between pharmacies in one region was considerably less than that between pharmacies in different regions ( Figure 1 ).
Because diabetic patients visit a pharmacy on average 5-6 times per year, community pharmacists are well placed to educate and support patients performing the complicated process of SMBG. Furthermore, there is evidence that a pharmaceutical care model for diabetes management, including training in SMBG, improves glycosylated hemoglobin and fasting plasma glucose. 5 Our findings suggest that the chance of receiving test strips differs between community pharmacies. Moreover, the role of community pharmacy in dispensing of test strips is significantly modified by region. Several reasons for this variability exist, not all under direct control of community pharmacists. Region-specific factors, for example, distribution of test materials by mail order, reimbursement of test strip use, and availability of qualified personnel, may have a major effect on the structure and process of diabetes care activities of individual pharmacies. Other factors, however, are under control of pharmacists, for example, sufficient training or attitudes toward diabetes being a treatable disease. Since the data on pharmacy and region were coded, the relative effect of these factors will have to be studied further.
Because of the observed differences between pharmacies, not all may experience the same barriers in dispensing of test strips. This underscores that implementing practice guidelines for diabetes in community pharmacy may require different approaches. Although our observations only apply to the Dutch situation, it is not unlikely that variability in dispensing of test strips also occurs in other countries. Factors such as reimbursement, qualified personnel, and training are not unique to the Netherlands.
Comment: therapy switching in patients receiving long-acting opioids
TO THE EDITOR: Given the paucity of pharmacoeconomic analyses of chronic pain management, the article by Berger et al. 1 concerning switching of opioid therapy was of considerable interest. Information from a large database of pharmacy claims suggested that noncancer patients receiving controlled-release (CR) oxycodone switched to an alternative analgesic less frequently than patients receiving CR morphine, with decreased overall healthcare costs. From this information, the authors surmised that healthcare costs could be reduced by minimizing drug therapy switches, with the implication that placing patients on oxycodone may help to achieve this goal.
The method employed by Berger et al. relies on adjusting survival curves with covariates. However, if some of the main effect correlates with the covariates, any adjustment violates the assumption of parallel regression, invalidating the results. This is important because the analysis of Berger et al. failed to examine several potential confounding variables, including the severity of disease (either the primary disease causing pain or the severity of comorbid conditions), differences in socioeconomic status, and quality of treatments.
Cost differences may arise from patients being nested within severity categories. Patients with more severe disease may have been prescribed one treatment (eg, morphine) over others and would be expected to have higher healthcare costs overall. Stratifying patients by cost categories and using a propensity scoring method would likely eliminate a significant amount of the differences between the therapy groups.
It is not clear whether there were disparities in healthcare plans (eg, percentage of patients in health maintenance organizations vs preferred provider plans) that might reflect differences in prescribing practices and socioeconomic status, an important predictor of morbidity. 2 Inappropriate prescribing and ineffective pain management are common, and patients prescribed one drug may be receiving better pain management than patients receiving the comparator, particularly if there are socioeconomic differences between groups. 3 The same argument applies to comorbid conditions, such as depression, in which treatment efficacy could significantly affect patient pain and opioid switching.
The differences in healthcare charges observed in Berger et al.'s cohort of patients appear large: for patients who switched opioids, costs were $9666 and $18 641 higher for patients without cancer and with cancer, respectively. In cost-utility models of long-acting opioids, there is only an incremental increase in drug cost per quality-adjusted life-year. 4 The differences in costs observed by Berger et al. likely reflect underlying differences in factors such as preexisting conditions, comorbidities, disease severity, and effectiveness of treatment rather than costs associated with drug switching.
Despite unanswered questions, this analysis is a positive step, and additional study is warranted to assess the complex relationship between chronic long-acting opioid use and total healthcare costs. Our current un-1752 s The Annals of Pharmacotherapy s 2004 October, Volume 38 www.theannals.com Figure 1 . Association between the community pharmacy and time to first test strips dispensed adjusted for age, gender, type of treatment, year of initiation of antidiabetic drug use, and co-medication, clustered by geographic region. The symbols represent different regions. Data from regions with only one study pharmacy (11 pharmacies) have been omitted.
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